Through a combination of transcriptomic, cytobiological, biochemical, pharmacological, and clinical experiments, we demonstrated that the FAO process is enriched in tamoxifen-resistant ER-positive BC cells with the increased enzymatic activity of CPT1A and that the CPT1A-FAO axis promotes the development of tamoxifen resistance in ER-positive BC cells. Here, CPT1A is linked to breast cancer.